Table 1 Clinical and laboratory features of enrolled patients divided according to seroconversion status for anti-Spike antibodies.
All patients N = 149 | Seroconverted N = 135 | Not seroconverted N = 14 | |
|---|---|---|---|
Age, years | 73 (17–93) | 73 (17–93) | 75 (50–86) |
Males/females | 79/70 | 73/62 | 6/8 |
Disease | |||
Warm AIHA, N (%) | 21 | 15 (71) | 6 (29)* |
Cold AIHA, N (%) | 16 | 14 (88) | 2 (12) |
ITP, N (%) | 25 | 24 (96) | 1 (4) |
Evans syndrome, N (%) | 11 | 7 (64) | 4 (36)* |
AA, N (%) | 11 | 11 (100) | 0 (0) |
PNH, N (%) | 19 | 19 (100) | 0 (0) |
LR-MDS, N (%) | 46 | 45 (98) | 1 (2) |
Laboratory values | |||
Neutrophils ×109/L | 3.1 (0.07–16) | 3.07 (0.07–16) | 3.6 (0.2–14) |
Lymphocytes ×109/L | 1.53 (0.37–5.8) | 1.5 (0.37–5.8) | 1.3 (0.51–5.2) |
Total IgG, mg/dL | 951 (207–2128) | 998 (207–2128) | 659 (256–1011)** |
Therapy | |||
No treatment, N (%) | 41 | 38 (93) | 3 (7) |
Steroids, N (%) | 31 | 24 (77) | 7 (23)*** |
Dose, mg/day | 7.5 (3–62.5) | 7.5 (2.5–37.5) | 10 (5–62.5) |
Cyclosporine, N (%) | 19 | 19 (100) | 0 (0) |
Complement inhibitor, N (%) | 20 | 20 (100) | 0 (0) |
Combined immunosuppressants, N (%) | 10 | 8 (80) | 2 (20)*** |
BM stimulating agents, N (%) | 28 | 26 (93) | 2 (7) |
< 12 months from rituximab | 5 | 2 (40) | 3 (60)*** |
Time from rituximab, months | 24 (1–156) | 26 (6–156) | 21 (1–72) |
Previous COVID-19, N(%) | 18 | 18 (100) | 0 (0)* |
